Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Vedolizumab Subcutaneous in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease
NCT06405087Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Oct 2025
- Primary completion
- Aug 2030
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of vedolizumab in ulcerative colitis (UC), Crohn's disease, sponsored by Takeda. Started Oct 2025; status: recruiting.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT06405087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06405087.